Essentials
• Inflammatory and cardiac diseases are associated with increased venous thromboembolism (VTE) risk.
• Our prospective study assessed rise in inflammatory or cardiac biomarkers and VTE risk.
• A greater 6-year rise in N-terminal natriuretic peptide is associated with increased VTE incidence.
• Volume overload or impending cardiac disease may contribute to VTE occurrence.
Summary. Background:
We previously showed that participants in the population-based Atherosclerosis Risk in Communities (ARIC) cohort with elevated levels of blood biomarkers of inflammation or cardiac disease were at increased risk of venous thromboembolism (VTE). Objective: We hypothesized that ARIC participants with larger 6-year increases in the levels of three biomarkers -C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and troponin T -would also have an increased subsequent risk of VTE. Methods: We measured changes in the levels of these biomarkers in 9844 participants from 1990-1992 to 1996-1998, and then identified VTEs through 2015. Results: A greater 6-year rise in the level of NT-proBNP, but not in that of CRP or troponin T, was significantly associated with increased VTE incidence over a median of 17.6 years of follow-up. After adjustment for other VTE risk factors, those whose NT-proBNP level rose from < 100 pg mL À1 to ≥ 100 pg mL À1 had a hazard ratio for VTE of 1.44 (95% confidence interval [CI] 1.15-1.80), as compared with the reference group with an NT-proBNP level of < 100 pg mL À1 at both times. This hazard ratio was
Introduction
Patients with major risk factors -such as surgery, immobility, and cancer -have a substantial risk of venous thromboembolism (VTE), i.e. deep vein thrombosis (DVT) or pulmonary embolism (PE) [1] . To a lesser degree, patients with inflammatory [2] or cardiac diseases [3, 4] , or even just elevated levels of blood biomarkers of inflammation or cardiac disease, also have an increased VTE risk. For example, we showed in the Atherosclerosis Risk in Communities (ARIC) Study that VTE incidence was approximately doubled in those in the top 10-20% of the distributions of baseline levels of either the inflammatory marker C-reactive protein (CRP), the cardiac myonecrosis marker troponin T, or the biomarker of myocardial stretch N-terminal pro-B-type natriuretic peptide (NT-proBNP), as compared with those with low levels of these biomarkers [5, 6] . The associations of these three biomarkers with VTE are probably not causal, but the identification of patients at increased risk may be relevant to VTE prevention. Also of scientific interest, but not yet studied, is whether increases in the blood levels of these inflammatory or cardiovascular biomarkers over time further identifies patients at risk of VTE. By analogy, several studies have clearly shown that an increase in the level of CRP, troponin T or NT-proBNP is associated with an increased risk of non-venous cardiovascular diseases [7] [8] [9] . We tested whether greater increases in the levels of these three biomarkers over a period of 6 years is associated with an increased subsequent 20-year risk of VTE in the ARIC Study.
Methods

Study sample
The ARIC Study enrolled 15 792 men and women aged 45-64 years from four US communities in 1987-1989 [10] . The ARIC Study conducted five subsequent examinations in 1990-1992 (ARIC Visit 2, 93% response), [1993] [1994] [1995] [1996] [1997] [1998] (ARIC Visit 4, 80% response), 2011-2013, and 2016-2017. Between examinations, ARIC interviewers contacted cohort members annually or semiannually via telephone to help find VTE events. The institutional review committees at each study center approved the methods, and staff obtained informed participant consent. This analysis examined biomarker changes from Visit 2 to Visit 4, and related those changes to VTE incidence after Visit 4.
Biomarkers
Trained field center technicians collected blood samples, immediately processed them, and stored serum and plasma at À 80°C until they were assayed. The biological and analytical variability of these biomarkers and their stability during frozen storage have been described previously [11] [12] [13] . In 2010, a research laboratory at the Baylor College of Medicine measured CRP, troponin T and NT-proBNP levels in plasma samples from Visit 4. In 2011-2013, a research laboratory at the University of Minnesota measured the same analytes in serum samples from Visit 2. An ARIC validation study showed that measured serum and plasma levels were nearly identical as determined with Deming regression analyses [14] .
The Baylor laboratory measured troponin T and NTproBNP levels on a Cobas e411 analyzer by use of the Elecsys high-sensitivity Troponin T assay [15] and the Elecsys proBNP II immunoassay (both from Roche Diagnostics, Indianapolis, IN, USA) [16] . The reliability coefficients for blind replicate measurements from a single Visit 4 blood draw were r = 0.98 for troponin T and r = 0.99 for NT-proBNP. The laboratory measured CRP with a nephelometric assay on the Siemens BNII analyzer (Dade Behring, Deerfield, IL, USA). The Visit 4 reliability for CRP was r = 0.99.
The University of Minnesota laboratory measured troponin T and NT-proBNP levels on a Roche Elecsys 2010 with sandwich immunoassays from Roche Diagnostics. It measured CRP with an immunoturbidimetric assay on the Roche Modular P analyzer. Visit 2 reliability coefficients were similar to those for the Baylor laboratory.
Numerous troponin T values were below the lower detection limit of 5 ng L À1 (66% in Visit 2 and 48% in Visit 4). A few NT-proBNP values were below the lower detection limit of 2.5 pg mL À1 (3% in both Visit 2 and Visit 4).
Other variables
The ARIC Study measured Visit 4 body mass index (BMI), cigarette use and postmenopausal hormone replacement therapy with standard methods. We obtained the Visit 4 estimated glomerular filtration rate (eGFR) by use of the Chronic Kidney Disease Collaboration algorithm involving creatinine and cystatin C [17] . We defined prevalent (at Visit 4) and incident (after Visit 4) coronary heart disease, heart failure and atrial fibrillation as previously described [6, 18] .
VTE classification
The ARIC Study followed participants through 2015 to identify possible VTE events (DVT or PE) resulting in hospitalization. Two physicians reviewed the discharge summaries, imaging and consultation reports, and other information, and classified VTEs according to standardized criteria [19] . The physicians also subclassified VTEs as unprovoked or provoked (associated with recent hospitalization for major trauma, cancer, or surgery, or with marked immobility) and as PE (with or without DVT) and DVT alone. Because upper-extremity DVTs were mostly attributable to indwelling catheters, we excluded them from the VTE definition for all analyses.
Analysis
As shown in Fig. 1 , from the 11 656 men and women who came to ARIC Visit 4, we excluded those with a history of VTE, those with current anticoagulant use, those with race/ethnicity other than black or white (owing to small numbers), a few without follow-up after Visit 4, and those with any of the three biomarkers missing, giving a total of 9854 participants for analysis. We also excluded the participants with the five largest positive and five largest negative changes in each of the three biomarkers, because these values were obvious outliers. This left 9844 participants for the analysis associating the change in each biomarker with incident VTE. Our aim was to associate the change in each biomarker between Visit 2 and Visit 4 with VTE incidence. However, because many values for troponin T were below the limit of detection, we could not readily calculate absolute changes in troponin T levels. In addition, published ARIC articles had established a convention of examining change according to categories with cutoffs of < 5, 5-13 and ≥ 14 ng L À1 for troponin T and a clinically based cutoff of 3 mg L À1 for CRP [7, 9] . We chose a cutoff of 100 pg mL
À1
for NT-proBNP. We chose the 100 pg mL À1 cutoff for NT-proBNP change a priori (i.e.
before exploring associations with VTE). We chose 100 pg mL À1 because: (i) our previous study showed that VTE risk increased above a baseline NT-proBNP level of > 100 pg mL À1 [6] ; and (ii) 100 pg mL À1 was the upper tertile cutoff for NT-proBNP change, and therefore yielded sufficient numbers in NT-proBNP change categories. The final categories for Visit 2-4 changes are shown in the tables. We used SAS for analysis. To describe the relationship of each biomarker with participant characteristics, we computed means and standard deviations for continuous characteristics and percentages for categorical characteristics within the biomarker change categories. We used Cox proportional hazards models to compute hazard ratios for incident VTE according to biomarker change categories. Model 1 was adjusted for age, sex, and race (white and African American). Model 2 was adjusted for age, race, BMI, eGFR, cigarette smoking (never, former, or current), and postmenopausal hormone use (women currently using hormones, women not using hormones, and men). We ran Model 2 for the full follow-up, and then restricted it to the first 10 years of follow-up. In addition to examining total VTE, we ran Model 2 with full follow-up for provoked and unprovoked VTE separately, and for isolated DVT and PE separately; we censored the follow-up time for those who had the complementary outcomes at their incidence dates. Then, we ran Model 3 for total VTE, further adjusting, as a time-dependent covariable, for coronary heart disease, heart failure or atrial fibrillation at baseline or incident during follow-up; the purpose was to determine whether the biomarker changes were associated with VTE independently of clinically recognized cardiac disease. In addition, we explored the relationship between the change in NT-proBNP, as a continuous variable, and incident VTE by using a restricted cubic spline, adjusted for the variables in Model 2. Spline knots were placed at recommended percentiles of 5, 27.5, 50, 72.5 and 95 [20] . When using a restricted cubic spline, one obtains a continuous smooth function that is linear before the first knot, a piecewise cubic polynomial between adjacent knots, and linear again after the last knot.
Results
As shown in Table 1 for NT-proBNP and in Tables S1  and S2 for CRP and troponin T, a substantial proportion of participants had increases in biomarker levels over the 6 years; fewer had decreases in biomarker levels. Although the relationships with sex and race varied among the three biomarkers, most VTE risk factors at Visit 4 were higher in those with the highest biomarker levels and in those who experienced increases in biomarker levels between Visit 2 and Visit 4.
Change in NT-proBNP level and VTE incidence
Over a median of 17.6 years (maximum: 19.9 years), we identified 527 incident VTEs. Consistent with our hypothesis, those whose NT-proBNP level increased from < 100 pg mL À1 to ≥ 100 pg mL À1 had 1.4-fold higher VTE risk (P < 0.05) than the reference group with an NT-proBNP level at both Visit 2 and Visit 4 of < 100 pg mL À1 (Table 2 ; Model 2). Those whose NTproBNP level was consistently ≥ 100 pg mL À1 had a > 1.6-fold higher VTE risk (P < 0.05). These hazard ratios were slightly higher during the first 10 years of follow-up ( Table 2 ). The few participants whose NTproBNP level decreased from ≥ 100 pg mL À1 to < 100 pg mL À1 had no increase in VTE risk as compared with the reference group. These patterns were largely similar for unprovoked and provoked VTE, and for DVT and PE subcategories, although the confidence intervals (CIs) for hazard ratios often overlapped 1 because of smaller numbers.
To further examine the shape of the association between NT-proBNP and VTE, we used a restricted cubic spline model and Model 2 adjustments. Within the majority of the distribution of NT-proBNP change, there was a strong positive association with VTE incidence (Fig. 2) . Because the NT-proBNP level may be elevated by cardiac disease, we reran Model 2 while also adjusting for time-dependent prevalent or incident coronary heart disease, heart failure, or atrial fibrillation (Model 3). The cumulative incidence percentages were approximately 16% for coronary heart disease, 20% for heart failure, and 18% for atrial fibrillation. After this adjustment, the hazard ratio associating an increase in NT-proBNP level with total VTE was 1.24 (95% CI 0.99-1.56) ( Table 2 ; Model 3). eGFR, estimated glomerular filtration rate; SD, standard deviation.
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Change in CRP level and VTE incidence Those whose CRP level was increased to ≥ 3 mg L À1 at both Visit 2 and Visit 4 had a 25% higher risk in Model 2 than the reference group whose CRP level was consistently < 3 mg L À1 (Table 3 ). This association was more apparent for unprovoked VTE and for DVT than for PE. In contrast, and contrary to our hypothesis, those whose CRP level rose from < 3 mg L À1 to ≥ 3 mg L À1 during the 6 years between visits did not have an increased VTE risk. Likewise, those whose CRP level fell between visits did not have an increased VTE risk as compared with the adjusted, in addition, for time-dependent prevalent and incident coronary heart disease, heart failure, and atrial fibrillation. *Per 1000 person-years. reference group. Adjustment for coronary heart disease or heart failure (Model 3) eliminated all associations of CRP level with total VTE. A restricted cubic spline analysis (not shown) also showed that continuous CRP change was not materially associated with VTE incidence.
Change in troponin T level and VTE incidence
Consistent with our hypothesis, people who had a 6-year increase in troponin T level from 5-13 ng L À1 to ≥ 14 ng L À1 had a 1.53-fold higher VTE risk (P < 0.05) than a reference group with a level of < 5 ng L À1 at both visits (Table 4 ). This was most apparent for DVT compared with PE and for provoked VTE. Contrary to our hypothesis, those whose troponin T level increased from < 5 ng L À1 to ≥ 5 ng L À1 had no increase in VTE risk. The relatively few people who had a troponin T level of ≥ 14 ng L À1 at Visit 2 had an increased VTE risk regardless of their troponin T level at Visit 4, but the 95% CIs for these hazard ratios overlapped 1. No hazard ratio for troponin T was significant after adjustment for cardiac disease in Model 3.
Discussion
We reported previously that baseline levels of NTproBNP, CRP and troponin T in the general population were positively associated with VTE incidence [5, 6] . In the present analysis, we found that a 6-year increase in only NT-proBNP level, and not in the the levels of other two biomarkers, was associated with subsequent VTE incidence over a median of 17.6 years, and that the association was even stronger for the first 10 years of followup. This positive association was independent of several VTE risk factors, and was generally consistent across VTE subtypes, but was attenuated by adjustment for the presence or development of non-venous cardiac disease. The longitudinal nature of the analysis strengthens our confidence that the association may be real. We are uncertain why single measures of CRP and troponin T were associated previously with incident VTE [5, 6] , but changes in these biomarkers were not. One possibility is that the original findings were spurious, because of some unrecognized confounding variable. Notably, in the original reports [5, 6] , the baseline NT-proBNP level appeared to be more strongly related to VTE in the ARIC Study than did the troponin T or CRP level. A second possibility is that within-person variability may be greater for CRP and troponin T than for NT-proBNP, resulting in our measurements of changes in those two biomarkers being suboptimal. Overall, the lack of longitudinal associations between CRP and troponin T changes and VTE incidence suggest that they, or the fundamental processes that they represent (low-level inflammation and cardiac injury), are not risk factors for VTE. adjusted, in addition, for time-dependent prevalent and incident coronary heart disease, heart failure, and atrial fibrillation. *Per 1000 person-years. Table 4 Incidence rates and hazard ratios (with 95% confidence intervals [CIs]) for incident venous thromboembolism (VTE) by 6-year change in troponin T level between Visit 2 (1990 Visit 2 ( -1992 and Visit 4 (1996 Visit 4 ( -1998 ; Atherosclerosis Risk in Communities Study Baseline troponin T level (Visit 2)
Six-year follow-up troponin T level (Visit 4) DVT, deep vein thrombosis; PE, pulmonary embolism. Model 1: adjusted for age, sex, and race. Model 2: adjusted for age, race, body mass index, estimated glomerular filtration rate, cigarette smoking, and sex/hormone use. Model 3: adjusted, in addition, for time-dependent prevalent and incident coronary heart disease, heart failure, and atrial fibrillation.
*Per 1000 person-years.
To our knowledge, no other study has documented in the general population that a higher NT-proBNP level or an increase in NT-proBNP level is associated with increased VTE incidence. Several clinical studies have, however, documented that acute PE patients with elevated NT-proBNP or BNP levels have increased rates of VTE recurrence or death, reflecting the fact that these are biomarkers of right ventricular dysfunction [21] [22] [23] . However, right ventricular dysfunction is relatively rare in the general population, and few ARIC participants had NTproBNP levels elevated to those seen in acute PE patients with right ventricular dysfunction. Clinical studies have also documented that not only the presence of heart failure [3] , but also the presence of elevated NT-proBNP levels in hospitalized heart failure patients [24] , is associated with increased VTE risk. Likewise, atrial fibrillation is associated positively with NT-proBNP level and with VTE [18] . A significant proportion of ARIC participants developed heart failure, coronary heart disease, or atrial fibrillation, and our adjustment for cardiac disease (Model 3) weakened the association between an increase in NT-proBNP level and VTE incidence. One may ask why these hypothesized pathophysiological pathways would apply to NT-proBNP but not to CRP and troponin T. Although CRP and troponin T levels are also positively associated with atrial fibrillation, the NTproBNP level is more strongly associated [18, 25, 26] . Although troponin T level is associated with heart failure similarly to NT-proBNP level, CRP level is not an independent predictor of heart failure in the ARIC Study [16, 27] . In addition, in the ARIC Study, the baseline NTproBNP level was a slightly stronger predictor of VTE than the troponin T or CRP level [5, 6] . Some drawbacks of our study warrant consideration. First, the laboratory precision for the three biomarkers was high, but we measured Visit 2 and Visit 4 biomarkers in separate batches and in samples frozen long-term at -80°C. Although previous evidence suggests that these biomarkers are stable in frozen samples [11] [12] [13] , drift in laboratory assay calibration or sample deterioration, if not uniform across the samples, may have affected our results in unknown ways. Second, biomarkers are subject to within-person variability [11, 28, 29] , either biological or random. Random variability may have obscured or weakened the estimated associations between biomarker changes and VTE. Third, although we adjusted for VTE risk factors identified previously in the ARIC Study, we may have overlooked some important confounding factors. Hemostatic factors related to VTE, such as factor VIII, von Willebrand factor, and D-dimer, may be correlated with the three biomarkers studied, but, unfortunately, the ARIC Study did not measure hemostatic markers at Visit 2 or Visit 4. Genetic variants that are associated with VTE are unlikely to be related to the biomarkers and should not confound our results. Major precipitants of VTE, such as cancer, surgery, trauma, and immobility, are difficult to document in cohort studies over decades of follow-up. We addressed these potential confounders by stratifying VTE cases into provoked or unprovoked, rather than by statistical adjustment for them. A final drawback is that we identified only VTE patients who were hospitalized, but unpublished ARIC data suggest that the vast majority of participants with first VTEs were hospitalized.
In conclusion, a 6-year increase in NT-proBNP level was associated with an increased subsequent incidence of VTE in the general population. The two most likely explanations for our results are that: (i) an increasing NTproBNP level reflects increasing subclinical volume overload and potentially increased venous stasis or subclinical PE that has gone unrecognized over time; or (ii) an increasing NT-proBNP level is a risk marker for impending cardiac disease that places patients at risk of VTE. Table S1 . Participant characteristics according to categories of 6-year change in CRP concentration between Visit 2 (1990 Visit 2 ( -1992 and Visit 4 (1996 Visit 4 ( -1998 , ARIC. Table S2 . Participant characteristics according to categories of 6-year change in troponin T concentration between Visit 2 (1990 Visit 2 ( -1992 and Visit 4 (1996 Visit 4 ( -1998 , ARIC.
